Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA1 | P00915 | 3/20 | 0.69 |
| ▸ | CA2 | P00918 | 3/20 | 0.69 |
| ▸ | XDH | P47989 | 2/20 | 0.69 |
| ▸ | CA12 | O43570 | 2/20 | 0.69 |
| ▸ | CA7 | P43166 | 2/20 | 0.69 |
| ▸ | CA9 | Q16790 | 2/20 | 0.69 |
| ▸ | CA14 | Q9ULX7 | 2/20 | 0.69 |
| ▸ | MAPT | P10636 | 3/20 | 0.64 |
| ▸ | P4HB | P07237 | 1/20 | 0.63 |
| ▸ | TUBB4A | P04350 | 2/20 | 0.60 |
| ▸ | TUBB | P07437 | 2/20 | 0.60 |
| ▸ | TUBA3C | P0DPH7 | 2/20 | 0.60 |
| ▸ | TUBA1B | P68363 | 2/20 | 0.60 |
| ▸ | TUBA4A | P68366 | 2/20 | 0.60 |
| ▸ | TUBB4B | P68371 | 2/20 | 0.60 |
| ▸ | TUBB3 | Q13509 | 2/20 | 0.60 |
| ▸ | TUBB2A | Q13885 | 2/20 | 0.60 |
| ▸ | TUBB8 | Q3ZCM7 | 2/20 | 0.60 |
| ▸ | TUBA3E | Q6PEY2 | 2/20 | 0.60 |
| ▸ | TUBA1A | Q71U36 | 2/20 | 0.60 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Isovanillic Acid Methyl Ester SCHEMBL29497236 | 1.00 | CA1 (0.69) | CA1CA2XDHCA12CA7 | |
| SCHEMBL10422069 | 0.89 | P4HB (0.64) | CA1CA2XDHCA12CA7 | |
| SCHEMBL24287563 | 0.85 | TUBB4A (0.57) | CA1CA2XDHCA12CA7 | |
| Methyl Vanillate SCHEMBL275939 | 0.85 | KMT2A (0.72) | CA1CA2XDHCA12CA7 | |
| Methyl Vanillate SCHEMBL25417789 | 0.85 | KMT2A (0.72) | CA1CA2XDHCA12CA7 | |
| Methyl Vanillate SCHEMBL31157843 | 0.85 | KMT2A (0.72) | CA1CA2XDHCA12CA7 | |
| Methyl Vanillate SCHEMBL29640509 | 0.85 | KMT2A (0.72) | CA1CA2XDHCA12CA7 | |
| Veratric Acid Methyl Ester SCHEMBL2050732 | 0.84 | MAPT (0.86) | CA1CA2XDHCA12CA7 | |
| Veratric Acid Methyl Ester SCHEMBL29573244 | 0.84 | MAPT (0.86) | CA1CA2XDHCA12CA7 | |
| SCHEMBL27575811 | 0.84 | TUBB4A (0.80) | TUBB4ATUBBTUBA3CTUBA1BTUBA4A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 466 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-103524433-A | Method for synthesizing gefitinib and intermediate thereof | TIANJIN PHARMACN MEDICAL TECHNOLOGY CO LTD | 2014-01-22 | — | — | CN | claimed |
| CN-103304491-A | Preparation method of gefitinib | LIANYUNGANG SHENGHE BIOTECHNOLOGY CO LTD | 2013-09-18 | — | — | CN | claimed |
| CN-101148439-B | Preparing method for gefitinib | UNIV SOUTHEAST | 2011-06-22 | — | — | CN | claimed |
| CN-101148439-A | Preparing method for gefitinib | UNIV SOUTHEAST (CN) | 2008-03-26 | — | — | CN | claimed |
| EP-1144408-A1 | SUBSTITUTED 1-(PIERIDIN-4-YL)-3-(ARYL) ISOTHIOUREAS THEIR PREPARATION AND THERAPEUTIC APPLICATION | PIERRE FABRE MEDICAMENT (FR) | 2001-10-17 | — | — | EP | claimed |
| WO-2000043391-A1 | SUBSTITUTED 1-(PIERIDIN-4-YL)-3-(ARYL) ISOTHIOUREAS THEIR PREPARATION AND THERAPEUTIC APPLICATION | PIERRE FABRE MEDICAMENT (FR) | 2000-07-27 | — | — | WO | claimed |
| US-20260108497-A1 | OXAZOLE COMPOUND AND PHARMACEUTICAL COMPOSITION | OTSUKA PHARMACEUTICALC., LTD. (JP) | 2026-04-23 | — | — | US | disclosed |
| US-12509470-B2 | Antiviral heterocyclic compounds | ENANTA PHARMACEUTICALS, INC. (US) | 2025-12-30 | — | — | US | disclosed |
| EP-2603098-B1 | METHOD OF IMPROVING STABILITY OF SWEET ENHANCER AND COMPOSITION CONTAINING STABILIZED SWEET ENHANCER | FIRMENICH INCORPORATED (US) | 2025-08-06 | — | — | EP | disclosed |
| US-20250179000-A1 | METABOTROPIC GLUTAMATE RECEPTOR POSITIVE ALLOSTERIC MODULATORS (PAMS) AND USES THEREOF | Sanford Burnham Prebys Medical Discovery Institute | 2025-06-05 | — | — | US | disclosed |
| US-20250073236-A1 | PYRIMIDINE COMPOUNDS CONTAINING ACIDIC GROUPS | APROS THERAPEUTICS INC (US) | 2025-03-06 | — | — | US | disclosed |
| CN-113563244-B | Substituted aza five-membered ring compound and application thereof in medicine | 广东东阳光药业股份有限公司 | 2025-01-10 | — | — | CN | disclosed |
| CN-113302184-B | 1,3, 4-Oxadiazolinone compounds and medicaments | 日本新药株式会社 | 2024-11-22 | — | — | CN | disclosed |
| WO-1994010258-A1 | CHEMILUMINESCENT ELECTRON-RICH ARYL-SUBSTITUTED 1,2-DIOXETANES | ABBOTT LABORATORIES (US) | 1994-05-11 | — | — | WO | disclosed |
| WO-1994002465-A1 | INHIBITORS OF c-AMP PHOSPHODIESTERASE AND TNF | RHONE-POULENC RORER LIMITED (GB) | 1994-02-03 | — | — | WO | disclosed |
| US-5208247-A | Antianaphylactic agents or septic shock | AMERICAN CYANAMID COMPANY (US) | 1993-05-04 | — | — | US | disclosed |
| EP-0530444-A1 | Aryl, amide, imide, and carbamate pyridine antagonists of platelet activating factor | AMERICAN CYANAMID COMPANY (US) | 1993-03-10 | — | — | EP | disclosed |
| CN-1069025-A | The aryl of platelet activating factor, acid amides, imide and carbamate pyridine antagonists | AMERICAN CYANAMID CO (US) | 1993-02-17 | — | — | CN | disclosed |
| US-5059610-A | QUINOLINE DERIVATIVES AND THEIR USE AS ANTAGONISTS OF LEUKOTRIENE D4 | RHONE-POULENC RORER PHARMACEUTICALS INC. (US) | 1991-10-22 | — | — | US | disclosed |
| US-4920132-A | Quinoline derivatives and use thereof as antagonists of leukotriene D4 | RORER PHARMACEUTICAL CORP. (US) | 1990-04-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12509470-B2 | Antiviral heterocyclic compounds | NR3C1, ZC3HAV1, HAVCR2 | CA1 2525/4885CA2 1633/4885XDH 620/4885 |
| US-20260108497-A1 | OXAZOLE COMPOUND AND PHARMACEUTICAL COMPOSITION | PDE7B, PDE4B, PDE1B | CA1 1395/4885CA2 270/4885XDH 100/4885 |
| US-20250179000-A1 | METABOTROPIC GLUTAMATE RECEPTOR POSITIVE ALLOSTERIC MODULATORS (PAMS) AND USES THEREOF | GRM3, GRM2, GRM1 | CA1 1732/4885CA2 990/4885XDH 3856/4885 |
| US-20250073236-A1 | PYRIMIDINE COMPOUNDS CONTAINING ACIDIC GROUPS | MAVS, TLR7, STING1 | CA1 4696/4885CA2 4262/4885XDH 267/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.